Current Report Filing (8-k)
June 21 2016 - 8:10AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
|
Date of Report (Date of Earliest Event Reported):
|
|
June 21, 2016
|
OPKO Health, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
001-33528
|
75-2402409
|
_____________________
(State or other jurisdiction
|
_____________
(Commission
|
______________
(I.R.S. Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
|
|
|
4400 Biscayne Blvd., Miami, Florida
|
|
33137
|
_________________________________
(Address of principal executive offices)
|
|
___________
(Zip Code)
|
|
|
|
Registrants telephone number, including area code:
|
|
(305) 575-4100
|
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01
|
|
Regulation FD Disclosure.
|
On June 21, 2016, OPKO Health, Inc., a Delaware corporation (the Company), issued a press
release announcing that the U.S. Food and Drug Administration approved the Companys New Drug
Application for RAYALDEE® (calcifediol) for the treatment of secondary hyperparathyroidism in
adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less
than 30 ng/mL.
A copy of the press release is attached hereto as Exhibit 99.1.
|
|
Item 9.01 Financial Statements and Exhibits.
|
(d) Exhibits
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
99.1
|
|
|
Press Release of the Company dated June 21, 2016
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
OPKO Health, Inc.
|
|
|
|
|
|
June 21, 2016
|
|
By:
|
|
Adam Logal
|
|
|
|
|
|
|
|
|
|
Name: Adam Logal
|
|
|
|
|
Title: Senior Vice President-Chief Financial Officer
|
Exhibit Index
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release of the Company dated June 21, 2016
|
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2023 to Apr 2024